Physician profile
John D Williams
NPI 1528068426
$4,641.65
in general payments reported to CMS, 2019-2025
48 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $798 · 2021: $1,418 · 2022: $398 · 2023: $474 · 2024: $325 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $560.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $423.07 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $417.24 | 2019-2023 | Ozempic |
| Lilly USA, LLC | $395.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $385.22 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $307.05 | 2020-2024 | Farxiga |
| Abbvie INC. | $167.21 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.26 | 2020-2024 | Ofev |
| Otsuka America Pharmaceutical, INC. | $141.66 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $126.86 | 2019-2022 | |
| Abbott Laboratories | $118.76 | 2023-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $117.69 | 2022-2024 | Hetlioz, Fanapt |
| Eisai INC. | $97.06 | 2020-2021 | |
| Optinose US, INC. | $89.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $86.71 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.